{"id":2843,"date":"2017-10-22T22:17:45","date_gmt":"2017-10-22T14:17:45","guid":{"rendered":"http:\/\/www.farmasi.asia\/?p=2843"},"modified":"2017-10-22T22:17:45","modified_gmt":"2017-10-22T14:17:45","slug":"informasi-keamanan-eso-who-19102017","status":"publish","type":"post","link":"https:\/\/apoteker.net\/blog\/informasi-keamanan-eso-who-19102017\/","title":{"rendered":"Informasi Keamanan Hasil Analisis Laporan Efek Samping Obat (ESO) dari WHO untuk Ruxolitinib, Desloratadine\/Loratadine, Ciprofloxacin-Enalapril dan Rosuvastatin-Ticagrelor"},"content":{"rendered":"

<\/p>\n

Apoteker.Net<\/strong> – Sehubungan dengan adanya informasi keamanan obat terbaru yang diperoleh dari WHO UMC-Signal, Badan Pengawas Obat dan Makanan (BPOM) Republik Indonesia menyampaikan informasi untuk tenaga kesehatan profesional sebagai upaya meningkatkan kehati-hatian dalam penggunaan obat di bawah ini untuk pasien.<\/p>\n

Informasi keamanan ini merupakan hasil analisis laporan Efek Samping Obat (ESO) dari WHO Global Database, yakni:<\/p>\n

    \n
  1. Ruxolitinib dan risiko neuropati perifer<\/li>\n
  2. Desloratadine\/Loratadine dan risiko peningkatan berat badan pada anak<\/li>\n
  3. Interaksi Ciprofloxacin dan Enalapril mengakibatkan peningkatan risiko gangguan ginjal akut<\/li>\n
  4. Interaksi Rosuvastatin dan Ticagrelor mengakibatkan risiko Rhabdomyolysis<\/li>\n

    \n<\/ol>\n

    Informasi di atas agar dapat menjadi perhatian profesional kesehatan khususnya Dokter dan Apoteker.<\/p>\n

    Terlampir surat resmi dari BPOM untuk disebarluaskan kepada anggota IDI dan IAI.<\/p>\n

    \"Surat<\/a>
    Klik di sini<\/a> untuk memperbesar gambar.<\/figcaption><\/figure>\n

    <\/p>\n

    \"Penguatan<\/a>
    Klik di sini<\/a> untuk memperbesar gambar.<\/figcaption><\/figure>\n

    <\/p>\n

    \"Penguatan<\/a>
    Klik di sini<\/a> untuk memperbesar gambar.<\/figcaption><\/figure>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":12,"featured_media":2847,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[11],"tags":[251,335],"class_list":["post-2843","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-obat-dan-penyakit","tag-bpom","tag-informasi-keamanan"],"aioseo_notices":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/i0.wp.com\/apoteker.net\/blog\/wp-content\/uploads\/2017\/10\/Header-Surat-Informasi-Keamanan-19-Oktober-2017.jpg?fit=905%2C362&ssl=1","_links":{"self":[{"href":"https:\/\/apoteker.net\/blog\/wp-json\/wp\/v2\/posts\/2843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/apoteker.net\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/apoteker.net\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/apoteker.net\/blog\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/apoteker.net\/blog\/wp-json\/wp\/v2\/comments?post=2843"}],"version-history":[{"count":0,"href":"https:\/\/apoteker.net\/blog\/wp-json\/wp\/v2\/posts\/2843\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/apoteker.net\/blog\/wp-json\/wp\/v2\/media\/2847"}],"wp:attachment":[{"href":"https:\/\/apoteker.net\/blog\/wp-json\/wp\/v2\/media?parent=2843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/apoteker.net\/blog\/wp-json\/wp\/v2\/categories?post=2843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/apoteker.net\/blog\/wp-json\/wp\/v2\/tags?post=2843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}